Actively Recruiting
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Led by Michigan State University · Updated on 2025-09-16
30
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
Sponsors
M
Michigan State University
Lead Sponsor
P
Pine Rest Christian Mental Health Services
Collaborating Sponsor
AI-Summary
What this Trial Is About
This protocol proposes an initial randomized clinical trial that includes all patients with suicidal ideation (SI) at baseline, and with SI as the primary outcome measure to examine whether Right Unilateral Low-Amplitude Pulse - Seizure Therapy (RUL LAP-ST) treatment has more magnitude and rate of remission of SI as conventional pulse amplitude Right Unilateral Electroconvulsive Therapy (RUL ECT) (based on our prior secondary analysis). Our central hypothesis is that RUL LAP-ST has significantly less cognitive/memory side effects (no memory side effects were noted in our prior studies for 500mA and 600mA) and thus is more favorable in terms of side effects compared to RUL conventional pulse amplitude ECT, while maintaining better anti-suicidal effect.
CONDITIONS
Official Title
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients referred for ECT by their primary psychiatrist with a valid clinical indication
- Male or female patients aged 18 to 90 years
- Current diagnosis of major depressive episode with suicidal ideation in major depressive, bipolar, or schizoaffective disorders
- Montgomery-Asberg depression rating scale score of 2 or higher on the suicidal ideation item
- Use of effective birth control for women of child-bearing potential
- Medically stable patients
- No need to change psychotropic medications during the study unless urgent
- Ability to fully participate in the informed consent process
You will not qualify if you...
- Unstable or serious medical conditions increasing risks of ECT or cognitive impairment
- Pregnant or breastfeeding women or those planning pregnancy during the study
- History of neurological disorders or brain conditions posing risks with ECT
- Presence of implanted devices that make ECT unsafe
- Clinical signs of delirium or dementia
- Active substance use disorder within one week before randomization
- ECT treatment within the past month or previous failure to respond to an adequate ECT course
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pine Rest Christian Mental Health Services
Grand Rapids, Michigan, United States, 49548
Actively Recruiting
Research Team
N
Nagy A Youssef, MD, PhD
CONTACT
J
Janelle M Kassien, LMSW
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here